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On a population-based level, the incidence of reactive arthritis (ReA) is 0.6–27/100,000.The
definition of ReA varies and its pathogenesis is not yet clear. Attempts in basic immunology
to suggest hypotheses for proliferation of forbidden B cell clones, molecular mimicry, and
involvement of cross-reactive antibodies are helpful but not sufficient. Importantly, for the
clinical diagnosis of the preceding infection, serology is widely used. Unfortunately, the
accuracy of associations between serologic findings and clinical conclusions is plagued
by poor standardization of methods. So far, few attempts have been done to examine the
pitfalls of different approaches. Here, we review several serologic techniques, their perfor-
mance and limitations. We will focus on serology for Yersinia, Campylobacter, Salmonella,
Shigella, and Chlamydia trachomatis because these bacteria have a longer history of being
associated with ReA. We also address controversies regarding the role of serology for
some other bacteria linked to autoimmune disorders.
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INTRODUCTION
Reactive arthritis (ReA) is a concept, not a well defined dis-
ease (1). It is an inflammatory sterile arthritis belonging to the
group of arthritides known as the spondyloarthropathies which
may develop within 2–4 weeks of the preceding gastrointestinal or
genitourinary infections (1–3). The terminology, epidemiology,
clinical presentation, antimicrobial treatment, and prognosis have
been reviewed elsewhere (1, 3, 4). Evidence for infection trigger-
ing the arthropathy is most convincing when microbe isolation
or antigen detection is successful. However, the search for the
infection is often delayed and the microbe may no longer be cul-
turable. Therefore, other options, e.g., serology are implied. Here,
we will examine only methodological aspects of serology because,
to our knowledge, such attempts have not yet been undertaken.
No review of literature can be exhaustive; rather we will pick
up examples of methodological solutions and demonstrate their
variability.
SEROLOGY FOR YERSINIA INFECTIONS
The first mention of “reactive arthritis”was done by Finnish physi-
cians in 1969 who described ReA as sterile arthritis after infection
with Yersinia enterocolitica (5).
An indirect hemagglutination test (IHA) was among the first
serological tests (6, 7) which is still in use albeit erythrocytes were
substituted with particles. In IHA, erythrocytes are sensitized with
heated extracts from bacteria. Antibodies to different Y. enterocol-
itica or Y. pseudotuberculosis serotypes, or biotypes, or serogroups
react with antigens and produce clumping. IHA and complement
fixation (CF) detect primarily IgM-class antibodies because these
are 10-valent compared to 2-valent IgG-class antibodies (having
only two sites for specific antigen binding). As a rule of thumb,
when the immune response is initiated, IgM-class antibodies reac-
tive with LPS will appear first. The response is followed by a class
switch and production of IgA- and IgG-class antibodies toward
protein structures. Since both IgM and IgG may react in IHA or
CF, these tests may not discriminate recent infection from past
exposure unless IgM are inactivated by sample pre-treatment.
Agglutination techniques are sensitive but their specificity could
be suboptimal if a crude extract antigen is used. For instance, sera
from brucellosis patients may react with particles sensitized with
the Y. enterocolitica serotype O:9 antigen. Differentiation between
these pathogens can be done, e.g., with EIA or immunoblot detect-
ing antibodies against plasmid-encoded Yersinia-associated outer
membrane proteins (OMPs) (8).
The result of a single agglutination technique may have a lim-
ited value. For example, in IHA human sera from blood donors
contained antibodies to both Yersinia serotypes in titers 4-512
whereas patient samples produced antibody titers 512-2048 and
32-256 against Y. enterocolitica O:3 and Y. enterocolitica O:9,
respectively (7). In Tanzania using microagglutination, Y. ente-
rocolitica antibodies to the serotype O:3 were found in 2.6% of
children and 0.9% of healthy adults, and to the serotype O:9 in 5.3
and 2.3%, respectively (9). But in countries where consumption of
pork per capita is higher, seropositivity among healthy population
could be also higher. Using EIA and immunoblot the seroposi-
tivity to Yersinia antigens was 19–31 and 33–43%, in Finnish and
German healthy volunteers, respectively (10).
Using Immunoblot IgA antibodies to a 36-kDa protein were
present in 18/19 ReA compared to 8/17 with non-arthritic yersin-
iosis. These antibodies persisted for 8–12 months (11). Although
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the difference is significant, these antibodies may not be a bio-
marker for the diagnosis of Yersinia-trigged ReA. Interestingly,
the avidity maturation of IgA antibodies toward whole bacte-
ria extracts or LPS was observed in ReA patients but not in
healthy convalescents. This phenomenon was not demonstrated
with antibodies toward plasmid-encoded proteins (12).
The interpretation of clinical significance of persisting IgG and
IgA antibodies to different antigens remains an issue for scientific
debate. The correlation of the persistence of Yersinia IgA to forma-
linized whole bacteria “OH” antigens (13, 14) with arthritis was
not confirmed later when antibodies to plasmid-encoded antigens
were studied in patients on the follow-up after 10 years (15). It was
concluded that neither IgA nor IgG persistence have a discernable
influence on the clinical course (15).
The matter of utmost interest is to know whether Yersinia truly
persists. What defines “chronic Y. enterocolitica infection” (16, 17),
and what are the symptoms of this clinical entity? If infection
indeed persists in a latent form, why can’t we demonstrate its acti-
vation upon immunosuppression of any kind? Chronic infection
was defined as a state of a negative culture and absence of agglu-
tinins but the presence of IgA and IgG antibodies to 36 and 46 kDa
virulence-associated proteins detected by immunoblot (16). By
definition, antibody persistence is not the same as infection per-
sistence; the question raised earlier (18). Y. enterocolitica O:3 was
maintained for several weeks in primary cultures of human syn-
ovial cells or fibroblasts (19, 20), however these experimental
models do not reflect the multi-functional, multi-cellular, and
multi-organ model of the human body. Bacterial LPS, heat shock
protein (HSP) (21) and the 16S ribosomal RNA sequences were
detected in patients with Y. enterocolitica O:3 triggered ReA (17),
however the proof of viable Yersinia in any body compartment is
missing.
Today our knowledge on the pathogenesis of infections caused
by Yersinia has been extended, and different adhesion molecules
have been described (22). The most important are invasin (Inv),
YadA (Yersinia adhesion A, previously known as Yop1), which is
the major adhesin, and Ail. Besides, there are several other pro-
teins, like YeuB, which also elicit immunological responses. After
acute infection all classes of antibodies to YeuB, Ail, YadA, and
Inv develop early with a peak on the second- third-weeks. These
antibodies were more prevalent in patients with gastroenteritis
compared to ReA patients (23). Yad of Y. enterocolitica has a colla-
gen binding activity. By contrast,Yad of Y. pseudotuberculosis binds
predominantly to fibronectin (22). Both species have been impli-
cated in ReA, although, only Y pseudotuberculosis serotypes O:1a
and O:3 have been reported to trigger ReA (3).
SEROLOGY FOR CAMPYLOBACTER INFECTIONS
Host-pathogen interaction has been recently reviewed (24, 25).
Campylobacter serology is highly variable. For example, in 40 diar-
rheal patients in whom C. jejuni was isolated, the seropositivity
was observed in 82, 62, and only 38% of patients, respectively
when immunofluorescence, CF, and agglutination techniques were
applied. Using paired sera samples from 15 patients a fourfold or
greater rise of titers was observed in only five (26). In a comparison
study between the CF and Western blot (WB) the seropositiv-
ity with CF was 88.6 and 28.5% for infected patients and blood
donors, respectively. Seven immunoreactive antigens (range 14–
67 kDa) were found, of which (29, 37, and 43 kDa) were detected
by 86, 84, and 91% of infected patients, respectively (27).
In the early 1980s, EIA-based techniques emerged (28–30). One
EIA (28) used heated and sonicated crude antigen preparations
from six C. jejuni strains; the other (29) used a single C. jejuni
isolate. In the latter, the common antigen was prepared by acid
extraction which was cross-reactive between different C. jejuni
and C. coli strains. In another EIA the acid extract was prepared
from three strains (30). The acid extract assays have been used for
routine diagnostics of Campylobacter infections ever since. Two
immunodominant antigens were characterized in the acid extract
as 30 and 60 kDa (30), however it could be assumed that it is a
mixture of multiple water soluble proteins. These EIAs were eval-
uated with human sera (30, 31) and with sera from immunized
rabbits (29). IgM and IgG-class antibodies were positive in only 73
and 52%, respectively in culture confirmed hospitalized patients
(31). The seroprevalence to this antigen in healthy blood donors
increases with age, reaching 60, 42, and 21% for the age group of
56–65 years for IgG, IgA, and IgM, respectively (32). These find-
ings have an important implication for interpretation of a single
positive result. Firstly, it is evident that, IgM-class antibodies may
persist, making an assumption of acute infection on the basis of a
single serum specimen imprecise. Secondly, diagnostic serology is
more informative in younger subjects.
Also in the 1980s, an EIA based on a mixture of LPS (more
precisely lipo-oligosaccharides (LOS)) from two strains was pub-
lished (33). This method resulted in only 70% sensitivity when
paired human sera were tested. When formalinized whole bacte-
ria were used, IgG and IgM antibodies from patients with recent
C. jejuni/coli enteritis were detected in 82 and 77%, respectively,
while antibodies were detected in 5% of healthy blood donors.
Sera from small children showed low reactivities. Interestingly, in
a comparison study better discriminatory power was achieved with
sonicated whole cell and ultracentrifuged sonicate than from acid
glycine extract (34).
Later, an EIA to detect antibodies to a heat stable antigen (pre-
sumably LOS) was described (35). The authors analyzed more
than 600 sera samples from 210 patients with recent infections
and found that IgG, IgA, and IgM EIA sensitivities were 71, 60,
and 80%, respectively at a specificity level of 90%. It was found
that IgG-class antibodies persisted at least 4.5 months with great
inter-individual variation, but for IgM and IgA antibodies decay
of immune response was evident by 2 months from the onset of
the infection.
Recently, a number of immunogenic antigens in Campylobacter
have been described (24). The major immunodominant anti-
gen is flagellin, the subunit protein of flagella. Also, major outer
membrane proteins (MOMP), periplasmic-associated membrane
proteins PEB1 (28 kDa), and PEB3 (30 kDa) as well as 47 and
84 kDa proteins are immunogenic. Novel methods detect anti-
bodies to several recombinant proteins of Campylobacter, e.g.,
MOMP, PEB4, PEB2, PEB1 OMP18, P39 in a line blot format
or conventional ELISA. For example, in pediatric patients with
GBS serodiagnosis based on recombinant antigens yielded better
specificity than tests using thermostable and whole cell-antigens
(36). The same has not yet been shown for ReA.
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Interestingly, Campylobacter infection can cause sequelae of the
nervous system, i.e., Guillain–Barré (GBS)/Miller Fisher syndrome
or lead to ReA. It has been reported that in GBS the antibodies to
nerve GM1b gangliosides may be cross-reactive with the LOS of
Campylobacter (24, 37). This may imply that Campylobacter serol-
ogy for GBS may need different antigen preparations compared
methods for ReA.
SEROLOGY FOR SALMONELLA INFECTIONS
Salmonella can more likely than Campylobacter cause ReA (1, 3,
25, 38). The first serodiagnostic test for Salmonella was developed
in 1896 after the observation that the sera of typhoid patients
clumped formalin-fixed bacteria from the host (39). These bacte-
rial preparations preserve the O-antigen and the Flagella. The test
has undergone several refinements (40). The history and evalua-
tion of this test has been recently reviewed (41). In the original
test, sera from those who presented with fever were mixed with
a suspension of killed S. typhi bacteria. If the antibodies (agglu-
tinins) to bacterial structures were present, agglutination of the
cell suspension occurred. Today, this test is used to support diag-
nosis of ReA. The test can demonstrate antibodies to O-, H-, or
Vi-antigens separately. As a rule of thumb, anti-O IgM antibodies
appear first, anti-H IgG antibodies are produced later and may
persist, anti-Vi antibodies can detect carriers (42). The slide test
modifies the Widal test, when the serum and cell suspension are
mixed and clumps are scored. A more advanced modification is
performed in tubes or microwells and requires an incubation step.
The Widal test can produce false reactions due to variability in
antigen preparation, too early sampling or technical difficulties of
interpretation and it has poor standardization and reproducibility
(41–43). False positive reactions might be common due to intrinsic
cross-reactivity with malaria and Enterobacteria infections. Inter-
estingly, in Nigerian patients who had a positive malaria smear,
were unvaccinated against S. typhi and who had negative S. typhi
stool isolation, the Widal test was positive in titers 1:40, 1:80, and
1:160 in 85, 12, and 3%, respectively. The corresponding figures
in patients without malaria were 45, 15, and 10% (43). These
data caution against the use of a single result to interpret Sal-
monella serology. As a matter of fact, historically, all tests based
on the measurement of antibody titers have relied on the com-
parison of acute and convalescent sera. It has been emphasized
that neither of the tests are interpretable unless the sensitivity and
specificity of the test for the specific laboratory are known (43).
The Widal test has lost some popularity in recent years (42). Dis-
appointingly, also newer tests for IgM and IgG antibody detection
lack sufficient sensitivity (max. 70%), and specify (max. 88%)
when tested on samples of patients with confirmed Typhoid fever
(44).
IHA utilizes erythrocytes sensitized with the Salmonella O-
antigen. The sensitivity is only 62% and specificity 98.2% with
positive and negative predictive values of 66.7 and 96.7%, respec-
tively (42). Counter current immunoelectrophoresis is based on
the visualization of a precipitation band of antigen-antibody
complexes. This method has a sensitivity close to Widal test (42).
A new approach to study Salmonella serology has been devel-
oped (41). Extracted LPS and flagellar antigens from four dif-
ferent strains each were applied to the gels for SDS-PAGE and
immunoblot. The reacting antibodies were detected by polyvalent
anti-human antibody. This method allows visualization of bands
against LPS and flagellin on separate gels, and the combination
of bands allows conclusion not only on the presence of specific
antibodies but to estimate the causative agent. The authors found
that all patients with culture confirmed salmonellosis produced
anti-LPS antibodies. Conversely, humoral response to flagellar “d”
antigens was seen in only 67% of patients (41).
Demonstration of antibodies to LPS of salmonellae other than
S. typhi is common practice, especially in S. typhimurium or S.
enteriditis infections, the two predominant serogroups responsible
for the majority of gastroenteritis in Europe. In patients who had
salmonellosis the LPS antibodies were equally detected with anti-
gens prepared from phenolic or trichloro acid extraction; however,
in the control group these antibodies were also highly prevalent
(45). Disappointingly, in veterinary studies using 937 samples and
a mix-ELISA test, no significant association was found between
positive serology and bacteriology (46).
SEROLOGY FOR SHIGELLA INFECTIONS
Shigella flexneri, sonnei, and dysenteriae were associated with ReA
on the basis of positive culture in patients with diarrhea (1, 47).
Shigella spp and E. coli are closely related bacteria that are not
distinguished with MALDI TOF nor when sequencing short DNA
fragments. Theoretically, antigen preparations as whole bacteria
sonicate, crude lysate, or even fractions of outer membrane are not
good enough for serology because antibodies may produce cross-
reactivity to gut microbiota (48). Interestingly, arthritogenicity of
Shigella flexneri 2a was not associated with the presence or absence
of antibodies toward epitopes of the cell wall (49). Advanced
Lumixex™ technology allowed simultaneous detection of spe-
cific antibodies to recombinant invasin plasmid antigens Ipa B,
C, and D as wells as to LPS from Shigella sonnei, flexneri 2a, and
dysenteriae (50). Although promising, this technology has not yet
been widely evaluated to support ReA diagnosis.
SEROLOGY FOR CHLAMYDIA TRACHOMATIS
The causative role of C. trachomatis in ReA is universally accepted,
although the pathogenesis is still unclear (51–54). It is assumed
that genital infection with C. trachomatis can result in a long-term
persistence of metabolically active organisms residing in synovial
tissues (52, 54). Amazingly, however, genetic material of only ocu-
lar serovars of C. trachomatis has been found so far in synovial
biopsies from arthritis patients (52). If true bacterial persistence
is the core feature of the C. trachomatis-trigged arthritis, could
this clinical entity be indeed referred as ReA? Or should it be
regarded as a separate entity because by definition ReA is the
reaction of the immunological system toward encountered (and
probably cleared?) infection.
Microimmunofluorescence (MIF) to detect antibodies to C.
trachomatis and C. pneumoniae was among the first serologic
methods (55, 56). A huge body of seroepidemiological studies
on Chlamydia using in-house and commercial MIF has been
published. The method utilizes elementary bodies (EB) that are
attached to the objective glass, to where specific immunoglobulins
bind, and further detected. To detect IgG and IgA antibodies, EBs
should be treated to remove LOS because they react with protein
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structures mostly. By contrast, IgM detection requires antigen with
LOS because IgM to carbohydrates as an early immune response
appear first. The advantage of MIF is its ability to discriminate
immunoresponses to different serovars (57). In a multicenter study
the interpretation of the results by MIF was found to be subjective,
and highly variable (58).
In the 1990s EIA-based techniques emerged. Those employed
treated EBs (59), or recombinant LOS antigens to detect genus-
specific antibodies (60) or synthetic peptides from immunodom-
inant MOMPs (61). Peptide-based immunoassay in diagnosis of
C. trachomatis triggered ReA was found useful (62), however, the
evidence of specific antibodies does not prove casualty. Some com-
mercial EIAs utilize MOMP, or HSP 60 (cHSP60). New formats,
e.g., line blot have also become available. Among five EIAs the
MOMP-based methods were superior in studies on tubal infertil-
ity and extra uterine pregnancy studies (63) but the problems of
standardization still remain unsolved. In our and other’s opinion
(64) whatever serology for C. trachomatis is used, it is of a limited
value for ReA.
QUESTIONS TO BE RESOLVED
Some bacterial species of the gut or skin microbiota have been
implicated as autoimmune triggers (65–70). The authors sug-
gested that sub-clinical urinary tract infection (UTI) by virtue of
molecular mimicry of the hemolysins of P. mirabilis and the amino
acid motif of the HLA-B27 antigen (expressed also on chondro-
cytes) may perpetuate immunopathology through cross-reactive
antibodies. The same argument for molecular mimicry has been
proposed as a causative link between Klebsiella pneumoniae and
ankylosing spondylitis (AS) in HLA-B27 positive subjects (71).
The analysis of the literature raises more questions than provides
answers, for example:
1. Why phylogenically non-related obligate or facultative intra-
cellular Salmonella, Campylobacter, or C. trachomatis may
trigger similar post-infectious arthropathies collectively called
ReA? What do they have in common?
2. Why are closely related enterobacteria, i.e., Proteus mirabilis
and K. pneumoniae, associated with different clinical entities,
the first with RA and the latter with AS?
3. Why is Salmonella but not E. coli [with an exception of only
a few case reports (72)], associated with ReA? And why P.
mirabilis with UTI but not E. coli? Indeed, why has E. coli UTI
been so rarely implicated in perpetuation of ReA, considering
its extremely high incidence?
4. Why do urogenital and enteric gram-negative bacteria trigger
ReA but many respiratory gram-negative don’t?
5. Why non-pathogenic ubiquitous yersiniae can not be “blamed”
for association with ReA, or could they?
6. Why diarrheagenic strains of E. coli are implicated in ReA (3)
but frequently encountered urinary E. coli are not?
CONCLUDING REMARKS
Here, some controversies of conventional serology to support the
diagnosis of ReA are illustrated. We advocate new studies to exam-
ine disease associations using microarray or proteomic platforms
to characterize immune profiles in ReA patients.
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